Assoc. Prof. Dr. Orhan Şencan

• Evaluation, diagnosis, treatment and folow-up of cancer patients (including breast, lung, esophagus, stomach, liver, pancreas, intestines, rectum, kidney, bladder, prostate, ovary, cervix, and other organs)

• Medıcal treatment of cancer including:
• Chemotherapy
• Immunotherapy and biologic agents
• Targeted therapy
• Hormonal therapy

▪ Yalcin S, Uslu R, Dane F, Yilmaz U, Zengin N, Buyukunal E, Buyukberber S, Camci C, Sencan O, Kilickap S, Ozdener F, Cevik D. Bevacizumab + capecitabine as maintenance therapy after initial bevacizumab + XELOX treatment in previously untreated patients with metastatic colorectal cancer: phase III ‘Stop and Go’ study results–a Turkish Oncology Group Trial. Oncology.85(6):328-35, 2013
▪ Demirkazik A, Asik M, Yalcin B, Dogan M, Buyukcelik A, Sencan O, Utkan G, Akbulut H, Icli F. The prognostic importance of Leucocytosis, thrombocytosis and serum cascular endothelial growth factor (VEGF) level in inoperable non-small cell lung cancer (NSCLC): A match-pair analysis. International Journal of Hematology and Oncology; 20:14-19, 2010
▪ Yaman E, Yalçın B, Utkan G, Akbulut H, Işıkdoğan A, Şencan O, Büyükçelik A, Pamir A, Demirkazık A, İçli F. Prognostic significance of serum matrix metalloproteinase 9 (MMP-9) levels in patients with Sarcomas. International Journal of Hematology and Oncology; 18:79-84, 2008
▪ Sencan O, Buyukcelik A, Yalcin B, Boruban MC, Akbulut H, Demirkazik A, Senler FC, Onur H, Icli F. The symptomatic benefit (the clinical benefit response) from the second-line chemotherapy in patients with advanced gastric adenocarcinoma. European Journal of Cancer Care 2008, 17, 26–32
▪ Boruban C, Sencan O, Akmansu M, Atik ET, Ozbek S. Metastatic gastrointestinal stromal tumor with long-term response after treatment with concomitant radiotherapy and imatinib mesylate.
Anticancer Drugs. 2007 Sep;18(8):969-72.
▪ Dogan M, Demirkazik A, Konuk N, Yalcin B, Buyukcelik A, Utkan G, Tek I, Akbulut H, Sencan O, Icli F.The effect of venous thromboembolism on survival of cancer patients and its relationship with serum levels of factor VIII and vascular endothelial growth factor: a prospectivematched-paired study. Int J Biol Markers. 2006 Oct-Dec;21(4):206-10.
▪ Boruban MC, Yasar U, Babaoglu MO, Sencan O, Bozkurt A. Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
▪ Boruban C, Yavas O, Altundag K, Sencan O. Synchronous presentation of nasopharyngeal and renal cell carcinomas. Int Braz J Urol. 2006 May-Jun;32(3):310-2.
▪ Gunes A, Coskun U, Boruban C, Gunel N, Babaoglu MO, Sencan O, Bozkurt A, Rane A, Hassan M, Zengil H, Yasar U. Inhibitory effect of 5-fluorouracil on cytochrome P450 2C9 activity in cancer patients. Basic Clin Pharmacol Toxicol. 2006 Feb;98(2):197-200.
▪ Icli F, Akbulut H, Uner A, Yalcin B, Baltalı E, Altinbas M, Coskun Ş, Komurcu S, Erkisi M, Demirkazik A, Senler FC, Sencan O, Büyükcelik A, Boruban C, Onur H, Zengin N, SakSD. Cisplatin plus oral etoposide (EoP) combination is more effective than paclitaxel in patients with advanced breast cancer pretreated with anthracyclines: a randomised phase III trial of Turkish Oncology Group. British Journal of Cancer, 92:639–644, 2005
▪ Yalcin B, Akbulut H, Buyukcelik A, Sencan O, Demirkazik A, Onur H, Senler FC, Dincol D, Icli F. The Effects of Chronomodulated Therapy with 5-Fluorouracil (5-Fu) and Folinic Acid (Fa) on the Toxicity and Quality of Life in Patients with Advanced Gastric Cancer. Biological Rhythm Research, 35 (4/5):259–268, 2004
▪ Dincol D, Samur M, Pamir A, Sencan O, Akbulut H, Yalçın B, Onur H, Demirkazık A, Şenler FÇ, Içli F. Prospective Randomized Comparison of the a.m. versus p.m. Daily Single Subcutaneous Administration of Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF). Cancer, 88:2033-6, 2000
▪ Arıcan A, İçli F, Akbulut H, Çakır M, Şencan O, Samur M, Açıkgöz N, Demirkazık A. The effect of two different doses of oral clodronate on pain in patients with bone metastases. Medical Oncology, 16:204-210, 1999,

• 1999: Oral Presentation Award at the 13th National Cancer Congress in Antalya, Turkey
• 1979-1981: High School Scholarship from the Scientific and Technical Research Council of Turkiye (TUBİTAK)
• 1978: Third Place in the Central Anatolia Region in the National Middle School Mathematics Competition by Scientific and Technical Research Council of Turkiye (TUBİTAK)

• American Society for Clinical Oncology (ASCO)’ expi
• European Society for Medical Oncology (ESMO)
• Turkish Society of Medical Oncology
• Turkish Oncology Group (TOG)
• Turkish Society of Internal Medicine (Member of Executive Committee between 2002-2004)
• Chamber of Physicians, Istanbul, Turkiye